Compass CEO Kabir Nath quit high-paying job to work on psychedelic pill for treating depression
In 2022, Kabir Nath quit his high-paying executive job at a pharmaceutical company to tackle a project that…
W Health Ventures closes Fund II at ₹700 crore, aims to build 8-10 healthcare startups
Unlike traditional venture capital funds that back pre-existing, high-growth startups for an equity stake, W Health’s company creation…
Lilly to buy psychedelic-drug firm AtaiBeckley
The pharma giant Eli Lilly and Company has agreed to buy the biotech firm AtaiBeckley, expanding its…
3 Companies Redefining Healthcare Innovation
This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)?
In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin…
AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AtaiBeckley…
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?
AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc…
Ketamine Revolution: Study Redefines Depression Treatment
Summary: For decades, the standard treatment for depression relied on antidepressants that targeted monoamines like serotonin and norepinephrine—drugs…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New…
Keto diet linked to short-term symptom relief in treatment-resistant depression
A study has found that the ketogenic diet — high fat and low carbohydrates — may help with…